Revenue Due Diligence
B2B SaaS · $1.8M ARR · Series A process beginning
📋
This Assessment Is For
A Founder · Pre-Series A · Goal: Raise at Fair Valuation With No Diligence Surprises
The product is strong.
The story has a concentration problem.
An investor-grade read on repeatability, scalability, and revenue quality, so the gaps get found by you now, not by a lead investor during the process.
Current ARR
$1.8M
Top 3 Customer Share
47%
NRR
102%
Forecast Accuracy
61%
Identifying details anonymised for illustration.
Reality
Risk
Investor Lens
Valuation
Two Versions of the Raise
Page 1 of 21 · Before the data, the stakes
Investors find the gaps in your revenue story. The question is whether you find them first.
This is what the fundraising process looks like depending on one decision: whether the gaps are addressed before the process starts.
If the Gaps Stay Unaddressed
6 Months
Pitch goes out. Early interest looks strong based on ARR and margin. Diligence begins and so do the questions about concentration and forecast variance that nobody had a clean answer for.
12 Months
The round closes smaller, later, or at a discount, if it closes in this window at all. Capital raised against unresolved gaps compounds the original narrative problem instead of solving it.
If the Gaps Are Addressed First
6 Months
Concentration risk is proactively disclosed with a clear mitigation narrative. Forecast discipline is tightened for one full quarter before the process begins. Materials are prepared with the hard questions already answered.
12 Months
The raise enters process with a defensible story. Process moves faster with fewer surprises. Capital is raised at a valuation that reflects the business's real strength, not its unaddressed gaps.
Business Reality
Page 2 of 21 · Not metrics. A map.
Here is your company through an investor's lens.
Vision
Clear, Credible
↓
Revenue Engine
$1.8M ARR, Partially Repeatable
↓
Customers
47% in Top 3, Concentration Risk
↓
Product
Strong, 74% Gross Margin
↓
Team
No Sales Leadership at This ARR Level
↓
Capital
13 Months, Raise Window Open
Where You Are Today
Page 3 of 21 · Their numbers, not benchmarks
What is actually true about this company's commercial story.
Current ARR
$1.8M
Top 3 Customer Share
47%
Concentration risk
NRR
102%
Healthy
Forecast Accuracy
61%
Below diligence threshold
Founder-Influenced Deals
52%
Elevated
Sales Leadership
None
Gap for stage
Gross Margin
74%
Strong
Runway
13 mo
What this actually means
NRR at 102% and gross margin at 74% are genuinely strong and will hold up well in diligence. But three customers represent nearly half of total ARR, forecast accuracy sits well below what a Series A investor expects, and there is no sales leadership at a stage where investors expect to see one. None of these are deal-breakers individually. Together, they tell a story of a company whose revenue quality looks better on the surface than it will once an investor's associate builds a cohort model.
What We Investigated
Before any conclusion, the research
This was researched, not guessed.
Every finding is built from specific inputs reviewed specifically for this company.
✓
Customer cohort by contract size
✓
Revenue concentration analysis
✓
4-quarter forecast vs actual
✓
Sales process documentation
✓
Comparable Series A diligence patterns
✓
Founder deal-involvement logs
✓
Leadership structure and gaps
✓
Intake responses
✓
Investor term sheet patterns at this ARR
✓
Cap table and runway model
Vision Alignment
Page 4 of 21
Your goal. What is between you and it.
Your Goal
Raise Series A at Fair Valuation, No Diligence Surprises
↓
What Is Preventing It
Concentration Risk and Forecast Unreliability
↓
What Must Change
Gaps Disclosed Proactively, Forecasting Tightened, Narrative Rebuilt
↓
Expected Outcome
A Raise That Reflects the Business's Real Strength
Primary Growth Friction
Page 5 of 21 · The primary constraint
Revenue Concentration and Forecast Risk
What diligence will find, and what disclosing it proactively changes.
What diligence will surface
Top 3 customers represent 47% of ARR, the largest being 21% alone · 4-quarter forecast variance averages 39%, well below investor expectations · 52% of closed deals had founder involvement in the final stage · No VP Sales or equivalent commercial leader in place
Observation
A 21% single-customer concentration is the kind of number that gets asked about directly in a partner meeting. Combined with a 39% forecast variance, the underlying question an investor will be evaluating is not whether this is a good company, it is whether they can trust what this team tells them about the next four quarters. Right now, the honest answer is not yet.
Can this be addressed before the process starts? Yes. The Wiremap Growth Plan sequences exactly how to build the proactive narrative and tighten forecasting in time.
The Constraint Stack
One visual. The whole chain.
The Symptom
Valuation Discount Risk
Shows Up As
Unresolved Diligence Questions
Caused By
Revenue Concentration + Forecast Variance
Which Produces
Investor Trust Gap
Root Cause
Gaps Not Identified Before Process Starts
Blind Spot Analysis
Page 6 of 21
What this is. What it is not.
You do NOT have
A product quality problem
A gross margin problem
An NRR problem
A fundraising readiness problem in principle
You DO have
An unaddressed narrative risk
Why this matters
74% gross margin and 102% NRR are genuinely strong numbers, they rule out product and unit economics as the problem. What remains is a narrative gap: the story this company tells about its revenue quality will be challenged in diligence, and not having clear answers ready shifts leverage to the investor.
Cost of Inaction
Page 7 of 21
Unaddressed diligence gaps have a price.
Concentration risk left unexplained reads as a red flag rather than a known, managed risk
Forecast variance discovered during diligence rather than disclosed proactively damages credibility broadly
Every gap found by the investor rather than disclosed by the company shifts negotiating leverage
A slowed or failed process costs months of runway and momentum that are hard to recover
In dollar terms
On an estimated $14M to $18M raise, the combined effect of unaddressed concentration risk and forecast unreliability is typically a 15 to 25% valuation discount, meaning $2.1M to $4.5M in foregone valuation that a structured pre-raise assessment can help recover.
Future State Simulator
Page 8 of 21
Two diligence processes. Same starting metrics.
Gaps Undisclosed
Forecast Accuracy
61%
Concentration Risk
Unaddressed
Diligence Speed
Slow
Valuation Discount Risk
15-25%
Gaps Proactively Addressed
Forecast Accuracy
85%+
Concentration Risk
Disclosed + Narrative
Diligence Speed
Fast
Valuation Discount Risk
Minimal
0
Now
Gaps unaddressed, raise not yet live
30
30 Days
Narrative rebuilt, forecast tightened
90
90 Days
One clean quarter of forecast accuracy
180
180 Days
Process begins with confidence
365
12 Months
Capital raised at fair valuation
Revenue Quality Assessment
Page 9 of 21 · What investors will find in the data room
Four dimensions of revenue quality. Scored.
Recurring vs One-Time
94%
94% of ARR is genuinely recurring subscription revenue. Strong. This will hold up well.
Revenue Predictability
61%
Forecast accuracy. A 39% average variance over 4 quarters will raise questions about process reliability.
Customer Concentration
47%
Top 3 accounts. The largest single account at 21% will be the first diligence question.
Net Revenue Retention
102%
Healthy and above 100%. This is a genuine strength that the concentration risk partially overshadows.
Commercial Due Diligence
Page 10 of 21 · How the commercial engine holds up under scrutiny
Five categories. Scored against Series A expectations.
CategoryFindingInvestor Concern Level
Sales ProcessPartially documented. Founder-dependent at close.Medium
ForecastingNo formal process. 39% average variance over 4 quarters.High
Commercial LeadershipNo VP Sales or equivalent at $1.8M ARR.Medium
Systems and DocumentationCRM in use. Weak pipeline hygiene. No playbook.Medium
Revenue RepeatabilityStrong on retention. Weaker on acquisition consistency.Low-Medium
Founder Dependency Analysis
Page 11 of 21 · Quantified
How much of the business relies on the founder to operate?
Investors underwrite the business, not the founder. High dependency is a structural risk that gets priced into the term sheet.
Deals with founder at close
52%
Key customer relationships
71%
Strategic decisions
88%
Forecasting and pipeline review
79%
Product roadmap ownership
45%
Investor read
The high dependency on the founder for customer relationships and forecasting will draw specific questions about what happens if the founder steps back from day-to-day sales. The hire plan for commercial leadership becomes a critical component of the Series A use-of-funds narrative.
Revenue Durability Score
Page 12 of 21 · How stable is this revenue actually?
Four dimensions. One honest read.
81
Retention Quality
42
Concentration Risk
38
Forecast Reliability
57
Commercial Independence
Growth Sustainability
Page 13 of 21 · Can growth continue at the rate implied by the raise?
Three questions every investor is asking.
Q1
Is the current growth rate repeatable without the founder?
Currently: no, 52% of deals close with founder involvement. This is a known risk with a clear fix: a VP Sales hire with a documented motion to inherit. That hire plan needs to be specific, not aspirational, and tied to the use of funds.
Q2
What happens to ARR if the largest customer churns?
At 21% of ARR, a single churn event would drop ARR from $1.8M to $1.42M. Investors will model this scenario. The answer needs to include both the mitigation plan and the pipeline that would backfill it.
Q3
Can this team forecast the business accurately at 2x this ARR?
Currently: 61% accuracy. Investors need to see one quarter of tightened forecasting before the process starts, not after. This is not about the number, it is about the process that produces it.
Commercial Red Flags
Page 14 of 21 · Board-level risks
Four flags. Each one manageable if addressed now.
⚑
Single-customer concentration at 21% of ARR
This will be the first question in every partner meeting. The answer must include contract length, renewal status, expansion opportunity, and what diversification looks like in the next 12 months.
⚑
39% average forecast variance over 4 quarters
Forecast miss at this scale signals a process problem, not just a timing issue. Investors will build their own model and apply a discount to the numbers they cannot verify.
⚑
No commercial leadership at $1.8M ARR
Investors expect to see a plan for this at Series A. A specific candidate, a defined role, and a clear budget allocation in the use-of-funds narrative turn this from a red flag into a credible plan.
⚑
Founder dependency at 52% of closed deals
Scale investors underwrite a team, not a person. This needs a documented motion that exists independently of the founder, or a timeline for building one as part of post-raise priorities.
Investor Confidence Dashboard
Page 15 of 21 · What investors would love, and what they would question
Both sides of the investor's scorecard.
What investors would love
74% gross margin, genuinely strong for this stage
102% NRR, product retention is real
94% recurring revenue, high-quality ARR composition
13 months runway, not a distressed raise
$1.8M ARR at a believable valuation entry point
What investors would question
Why does one customer represent 21% of ARR?
Why is forecast accuracy at 61% after 4 quarters?
Who runs sales after the founder is no longer in every deal?
What is the plan if the largest account does not renew?
Can this team deliver the growth implied by the raise size?
Valuation Impact Analysis
Page 16 of 21 · What increases value. What suppresses it.
The commercial factors that directly affect your term sheet.
What increases valuation
Strong gross margin (74%), commands a premium multiple
NRR above 100%, signals product-market fit
Proactive gap disclosure, builds investor trust
One clean quarter of forecast accuracy before process starts
A specific VP Sales hire plan in the use of funds
What suppresses valuation
21% single-customer concentration, discovered, not disclosed
39% forecast variance, signals process unreliability
No commercial leader, raises execution risk question
Founder dependency in closing, limits scalability narrative
Net valuation impact
Address the four suppression factors before the process starts, and the raise enters on the strength of the genuinely good metrics, 74% margin, 102% NRR, 94% recurring, rather than getting dragged into a negotiation about the gaps.
Acquisition Readiness Assessment
Page 17 of 21 · How an acquirer would view this company
Not just a VC raise, the acquirer lens.
Strategic acquirers run the same diligence as investors. This is how this company would score on the dimensions that matter most to them.
Technology & Product
Strong
74% margin signals clean architecture and real differentiation.
Customer Quality
Medium
102% NRR is strong. Concentration risk limits perceived durability.
Revenue Repeatability
Developing
Founder dependency and forecast variance signal a motion not yet independent.
Team Independence
Low
High founder dependency raises post-acquisition integration risk for most buyers.
Commercial Documentation
Weak
No playbook, weak pipeline hygiene. This would be a priority request in any LOI process.
Market Position
Strong
Clear differentiation and customer retention validate market position.
Opportunity Heatmap
Page 18 of 21
Five levers. Ranked by valuation impact.
ActionValuation ImpactDifficultyTimeline
Build proactive concentration narrativeHighLow30 days
Tighten forecasting for one full quarterHighMedium90 days
Define VP Sales hire plan and timelineHighLow30 days
Document the sales motion and playbookMediumMedium60 days
Diversify revenue beyond top 3 accountsHighHigh90-180 days
The first three actions cost no money and take under 90 days. The Wiremap Growth Plan sequences them against your specific fundraising timeline.
ROI Dashboard
Page 19 of 21
Same ARR. Very different valuation.
Gap-Unaddressed Valuation
$14M
→
Gap-Addressed Valuation
$17.5M
Difference
+$3.5M unlocked
Unlock Sequence
Page 20 of 21 · Strategic direction, not execution detail
Three priorities. In order.
Priority 01
Build a proactive concentration risk narrative before any investor asks about it
Why it matters
Disclosed risk reads very differently than discovered risk. Answering the concentration question before it is asked shifts the conversation from concern to confidence.
Expected impact
Diligence moves faster and negotiating leverage stays with the founder.
Priority 02
Tighten the forecasting process for one full quarter before entering the raise
Why it matters
One clean quarter of forecast-to-actual performance is worth more in diligence than any amount of explanation about why historical numbers were off.
Expected impact
Forecast accuracy above 85% signals a process, not a guess.
Priority 03
Define the VP Sales hiring plan and timeline, tied to use of funds
Why it matters
Investors do not need the hire in place, they need a credible, specific plan tied to how their capital gets deployed.
Expected impact
A leadership gap becomes a funded initiative rather than an unresolved risk.
What Comes Next
Page 21 of 21 · What resolving this is worth
Find My Constraint →
ROI Dashboard
The cost of this constraint, quantified.
Every week this constraint stays unresolved is a week the underlying cost compounds. Here is what the numbers look like when the constraint is named, not estimated.
Monthly Cost Unresolved
$35K–$65K
Pipeline inefficiency and conversion loss
6-Month Compounding Cost
$210K–$390K
Across hiring, pipeline, and runway
Value of Resolving It
$500K–$1.2M
Recovered ARR potential within 12 months
The cost of the assessment in context
This Revenue Due Diligence report cost $1,249. The constraint it identified is costing an estimated $35K–$65K every month it stays unresolved. The return on this assessment is not theoretical. It is structural.
Page 22 of 21 · What to do first
Find My Constraint →
Strategic Priorities
Three actions. In this order.
Not ten recommendations. The three moves that address the root constraint in the sequence that creates the most leverage. Start with Priority 01 before moving to 02.
Priority 01 · This Week
Address the top-3 concentration risk before the raise process starts
If your top three customers represent more than 40% of ARR, close one mid-market account outside those three before the first investor call. One additional account changes the concentration story from a risk to a managed transition.
Priority 02 · This Month
Build a proactive disclosure narrative for every gap in this report
Investors find gaps. The question is whether you found them first. For every risk identified in this report, write a single paragraph covering: what it is, why it exists, and what is already being done about it. Proactive disclosure builds trust. Discovered gaps destroy it.
Priority 03 · Next 90 Days
Improve forecast accuracy to above 80% for the quarter before the raise
Forecast accuracy is one of the clearest signals of commercial maturity investors look for. If your last four quarters averaged below 75% accuracy, building a more formal forecast process and achieving one clean quarter above 80% before the raise will directly affect your valuation.
Page 23 of 21 · What comes next
Find My Constraint →
Your assessment milestone
When to run the next assessment.
Not a date. A trigger. When this specific commercial signal appears, the next constraint is ready to be assessed.
Milestone Trigger
When the raise closes and the commercial story has been validated by investors in diligence, the next assessment should focus on scaling the motion that got you funded.
Watch for these signals before the milestone
Top-3 concentration drops below 35% of total ARR
Forecast accuracy above 80% for one full quarter
NRR is above 100% and stable for 2+ quarters
Non-founder commercial leadership is in place or actively hiring
The next assessment
GTM Risk Intelligence
$749 · 7 days · For scaling teams where the commercial motion needs to be repeatable and documented before the next hire
Start GTM Risk Intelligence →
Page 21 of 21
The assessment is done. Here is where that puts you.
1
Awareness
2
Assessed
You are here
Planned
Next
4
Execution
5
Optimization
6
Scale
Days 1-30
🔒
Days 31-60
🔒
Days 61-90
🔒

Detailed milestones, owner assignments, and KPIs available in the Wiremap Growth Plan.

The Wiremap Growth Plan

Convert this assessment into a step-by-step pre-raise plan, weekly priorities, KPIs, and a clear sequence timed against your fundraising window.

⚡ A real fragment, Week 1 of your plan, if purchased
Owner
Founder
Action
Write the proactive concentration narrative. One page covering: what makes the top 3 accounts sticky, contract terms and renewal status, the active pipeline that diversifies the base in the next 12 months.
KPI
Concentration narrative ready to share in a partner meeting by end of week
Done When
The answer to "why does one customer represent 21%?" takes under 60 seconds to give with confidence
This is what is inside, sequenced for every week against your specific fundraising timeline. Generative AI cannot produce this without the assessment behind it.
Recommended next health check: Before your raise process formally begins, or in 90 days, whichever comes first. Segment narrative shifts need real evidence behind them before they reach an investor's inbox.
Recommended
90-Day Growth Transformation
Best for a major growth milestone.
$448
  • Everything in the 60-Day plan
  • Full pre-raise sequencing roadmap
  • Investor readiness framework
60-Day Growth Acceleration
Best for multiple gap closures.
$358
  • Everything in the 30-Day plan
  • Cross-functional sequencing
  • Progress checkpoints
30-Day Growth Sprint
Best for the concentration narrative.
$178
  • Weekly priorities
  • KPI tracking
  • Narrative framework
Ask About the Growth Plan → Run My Own Assessment